TrialWorld journal of gastroenterology2013

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

Vanja Vaccaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.